Skip to main content

Could CBD Lead To The Development Of Safer Antipsychotic Medications?

Antipsychotic medications are important for managing a number of different psychiatric ailments, including bipolar disorders, schizophrenia, and even dementia. These drugs can greatly improve the manageability of symptoms that often distort one’s experience of reality. They can also create major mood disruptions and lead to a number of behavioral and emotional difficulties.

Antipsychotic and anti-psychosis medications can be life-changing for people with such disorders, enabling them to live more normal and manageable lives without their symptoms taking over. These drugs work by regulating neurotransmitters in the brain so that naturally occurring imbalances and dysfunctions no longer disrupt mental and emotional processes.

Often, reaching this outcome is much easier said than done; it can take a lot of time to find courses and combinations of treatments that work. It’s sometimes necessary to make adjustments to find the right balance for the individual and it’s not unusual for outcomes to change after periods of time, requiring further adjustments.

Side effects of these drugs can also cause their own challenges. Many antipsychotic drugs cause tremor or shaking, slowed thinking, sexual dysfunction, fatigue or drowsiness, and weight gain. Such unpleasant or disruptive side effects can also make it difficult for those being treated to be consistent in their dose. It’s not unusual for patients to feel frustrated with side effects or other aspects of their treatment, and they can be eager to get off medication as a result.

Additionally, the positive effects of these drugs can lead patients to feel that they are well enough to discontinue their treatment, which then results in relapses and setbacks, the consequences of which can be quite serious. Without adequate support and treatment resources, psychiatric ailments can be as debilitating as any physical disease.

This is why researchers are working hard to find antipsychotic treatment options that lack severe side effects and provide a better level of manageability. Better antipsychotic medications could ensure that patients are not eager to make changes or abandon their treatment programs. Fortunately, scientists are now finding that cannabidiol’s unique properties may provide a stepping stone to an effective, low-risk antipsychotic treatment option.

Cannabidiol has been tested in studies that examine its pharmacological effects in subjects exhibiting psychotic-like symptoms. One study found that CBD was able to regulate neurotransmitters in a way that was similar to some atypical antipsychotic drugs.

Though many more studies and clinical tests will be needed to confirm the reliability of potential CBD antipsychotic treatments, its notable safety profile may make it optimal for patients who struggle with current pharmaceutical options.

It’s certainly not appropriate to say psychosis is an answer to the question of what can CBD cure, but early findings show a great deal of promise. Perhaps CBD can benefit some of the most difficult conditions people can live with.

Manic episodes, severe mood swings, hallucinations, and paranoia can be as debilitating as any chronic physical illness. If CBD can actually reduce and inhibit these symptoms, without the major side effects of conventional drugs, it could be a groundbreaking development in mental health treatments.

Hopefully, studies will progress and we’ll soon know with better certainty what CBD can do for the treatment of these serious psychiatric conditions.

Original Article Source: https://blog.puredosage.com/what-is-cbd/development-of-safer-antipsychotic-medications

Comments

Popular posts from this blog

Cannabis Watch: Canopy Growth To Book Charge Of Up To $568 Million As Marijuana Restructuring Continues

Canopy Growth Corp. said early Thursday it was halting a range of operations across three continents and expects its restructuring plans to result in a charge of up to C$800 million (567.9 million) in the fiscal fourth quarter. U.S.-traded shares US:CGC CA:WEED of the cannabis company fell 1.9% in afternoon trading. Canopy said it was selling operations in Africa, curtailing cultivation of hemp in the U.S. and Columbia, and shutting down an indoor production facility in Canada. The announcement will result in 85 job cuts, the company said. “When I arrived at Canopy Growth in January, I committed to conducting a strategic review in order to lower our cost structure and reduce our cash burn,” Canopy Chief Executive David Klein said in a statement. Read: As cannabis industry stays largely quiet on coronavirus, this CEO has been sounding the alarm Canopy’s restructuring announcement was expected by investors, Cowen analyst Vivien Azer wrote in a note to clients Thursday. Azer rate...

Mormon Church Faces Potential Lawsuit Over Medical Marijuana Opposition

Political committees concerned with marijuana law reform in four states have waged an information war over the past year, first to qualify cannabis initiatives for the ballot, and then to support or oppose those measures in the lead-up to last week’s midterm elections. In total, over  $12.9 million in cash and in-kind services was spent attempting to convince voters about these marijuana ballot measures. Now that voters have had their say, Marijuana Moment decided to calculate how much each “yes” and “no” vote cost the committees on either side of the debate. Our calculations are based on dollars raised and disclosed before the election, since final totals of actual expenditures won’t be available until December or January reports required in the states that voted on cannabis. Michigan In Michigan, where voters approved marijuana legalization , our calculations show that the two anti-legalization committees spent about $1.28 per “no” vote, as they raised $2.37 million for ...